Condition: Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Sponsor: Ono Pharmaceutical Co., Ltd.
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
This description comes directly from the study's public registry record.
North America Clinical Trial Support Desk · +18665877745(Toll-Free) · clinical_trial@ono-pharma.com
International Clinical Trial Support Desk · +17162141777(Standard) · clinical_trial@ono-pharma.com
Always discuss trial participation with your own doctor first.
| Aichi Cancer Center Hospital | Nagoya, Aichi-ken, Japan | Recruiting |
| Nagoya University Hospital | Nagoya, Aichi-ken, Japan | Recruiting |
| Akita University Hospital | Akita, Akita, Japan | Recruiting |
| National Cancer Center Hospital East | Kashiwa-shi, Chiba, Japan | Recruiting |
| Kyushu University Hospital | Fukuoka, Fukuoka, Japan | Recruiting |
| Hokkaido University Hospital | Sapporo, Hokkaido, Japan | Recruiting |
| Tokai University Hospital | Isehara-shi, Kanagawa, Japan | Recruiting |
| Kumamoto University Hospital | Kumamoto, Kumamoto, Japan | Recruiting |
| University Hospital Kyoto Prefectural University of Medicine | Kyoto, Kyoto, Japan | Recruiting |
| Tohoku University Hospital | Sendai, Miyagi, Japan | Recruiting |
| Okayama University Hospital | Okayama, Okayama-ken, Japan | Recruiting |
| Kindai University Hospital | Osaka Sayama-shi, Osaka, Japan | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06547528